MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-17-2026
IQVIA Holdings Cost of Revenue 2011-2026 | IQV
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue IQVIA Holdings
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10.9 B | 10 B | 9.74 B | 9.38 B | 9.23 B | 7.5 B | 7.3 B | 6.75 B | 6.3 B | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 10.9 B | 6.3 B | 8.57 B |
Quarterly Cost of Revenue IQVIA Holdings
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.69 B | 2.53 B | - | 2.52 B | 2.49 B | 2.44 B | - | 2.43 B | 2.44 B | 2.4 B | - | 2.32 B | 2.33 B | 2.32 B | - | 2.25 B | 2.32 B | 2.29 B | - | 1.8 B | 1.7 B | 1.82 B | - | 1.85 B | 1.8 B | 1.75 B | - | 1.68 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 913 M | - | - | - | 859 M | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.69 B | 859 M | 2.09 B |
Cost of Revenue of other stocks in the Diagnostics research industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
162 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
ICON Public Limited Company
ICLR
|
3.97 B | $ 98.33 | 0.9 % | $ 8.11 B |  Irlanda |
|
Akumin
AKU
|
608 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Aspira Women's Health
AWH
|
3.86 M | - | -6.19 % | $ 10.5 M |  USA |
 |
Brainsway Ltd.
BWAY
|
6.6 M | $ 13.71 | -0.22 % | $ 99.4 M |  Israel |
 |
Bioventus
BVS
|
180 M | $ 8.62 | 0.23 % | $ 574 M | USA |
 |
DexCom
DXCM
|
1.86 B | $ 64.24 | -1.56 % | $ 25.1 B | USA |
 |
Castle Biosciences
CSTL
|
60.2 M | $ 25.56 | 0.95 % | $ 710 M | USA |
 |
CareDx, Inc
CDNA
|
45.5 M | $ 17.01 | 3.4 % | $ 906 M | USA |
 |
Accelerate Diagnostics
AXDX
|
9.45 M | - | -61.36 % | $ 2.46 M | USA |
 |
Exact Sciences Corporation
EXAS
|
984 M | $ 103.57 | 0.29 % | $ 19.5 B | USA |
 |
Guardant Health
GH
|
349 M | $ 85.49 | 1.75 % | $ 10.7 B | USA |
 |
Global Cord Blood Corporation
CO
|
183 M | - | - | $ 399 M |  China |
 |
Genetic Technologies Limited
GENE
|
276 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
194 M | - | 0.12 % | $ 80.1 M | China |
 |
Fulgent Genetics
FLGT
|
176 M | $ 14.77 | 0.61 % | $ 447 M | USA |
 |
Danaher Corporation
DHR
|
10 B | $ 187.32 | 0.57 % | $ 134 B | USA |
 |
Biocept
BIOC
|
28.4 M | - | -13.05 % | $ 7.29 M | USA |
 |
Heska Corporation
HSKA
|
146 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
4.57 M | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
1.51 B | $ 118.94 | 2.92 % | $ 18.9 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
7.37 B | $ 199.7 | -0.46 % | $ 22.2 B | USA |
 |
QIAGEN N.V.
QGEN
|
801 M | - | - | $ 10.6 B |  Niderland |
 |
Agilent Technologies
A
|
2.91 B | $ 111.51 | -0.06 % | $ 33.9 B | USA |
 |
BioNano Genomics
BNGO
|
30.4 M | $ 1.11 | -0.89 % | $ 1.41 M | USA |
 |
DarioHealth Corp.
DRIO
|
14.4 M | $ 9.0 | -0.99 % | $ 255 M | Israel |
 |
Neogen Corporation
NEOG
|
473 M | $ 9.09 | -2.78 % | $ 1.97 B | USA |
 |
Chembio Diagnostics
CEMI
|
38.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Pacific Biosciences of California
PACB
|
114 M | $ 1.33 | 4.72 % | $ 399 M | USA |
 |
Co-Diagnostics
CODX
|
4.18 M | - | - | $ 79.8 M | USA |
 |
DermTech
DMTK
|
15 M | - | -11.32 % | $ 2.94 M | USA |
 |
Personalis
PSNL
|
57.8 M | $ 6.72 | 1.97 % | $ 398 M | USA |
 |
NeoGenomics
NEO
|
413 M | $ 7.88 | -1.25 % | $ 1.01 B | USA |
 |
Enzo Biochem
ENZ
|
17.3 M | - | -8.98 % | $ 14.8 K | USA |
 |
Natera
NTRA
|
158 M | $ 187.85 | -1.29 % | $ 18.5 B | USA |
 |
Sotera Health Company
SHC
|
518 M | $ 13.42 | 0.71 % | $ 3.81 B | USA |
 |
Invitae Corporation
NVTA
|
92.8 M | - | - | $ 21.2 M | USA |
 |
OPKO Health
OPK
|
495 M | $ 1.19 | 2.59 % | $ 826 M | USA |